These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33787591)

  • 1. Efficacy of rivaroxaban for the treatment of Chinese patients with acute pulmonary embolism: A retrospective study.
    Wang L; Jiang S; Li C; Xu Z; Chen Y
    Medicine (Baltimore); 2021 Apr; 100(13):e25086. PubMed ID: 33787591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial.
    Barco S; Lankeit M; Binder H; Schellong S; Christ M; Beyer-Westendorf J; Duerschmied D; Bauersachs R; Empen K; Held M; Schwaiblmair M; Fonseca C; Jiménez D; Becattini C; Quitzau K; Konstantinides S
    Thromb Haemost; 2016 Jul; 116(1):191-7. PubMed ID: 27010343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of rivaroxaban for pulmonary embolism.
    Jia J; Xue SM; Xu N
    Medicine (Baltimore); 2019 Apr; 98(16):e15224. PubMed ID: 31008951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy: an academic centre experience.
    Paczyńska M; Kurnicka K; Lichodziejewska B; Goliszek S; Dzikowska-Diduch O; Sobieraj P; Burzyński Ł; Kostrubiec M; Pruszczyk P; Ciurzyński M
    Kardiol Pol; 2016; 74(7):650-6. PubMed ID: 26779849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
    Prins MH; Bamber L; Cano SJ; Wang MY; Erkens P; Bauersachs R; Lensing AW
    Thromb Res; 2015 Feb; 135(2):281-8. PubMed ID: 25483215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism.
    Duan L; Zhang N; Yan H; Guo Y; Hong C; Yang X; Su X; Chen R; Zhou Y; Zhong N; Liu C
    Clin Chim Acta; 2016 Aug; 459():25-29. PubMed ID: 27155586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program.
    Matsuo H; Prins M; Lensing AW; Fujinuma EW; Miyamoto Y; Kajikawa M
    Curr Med Res Opin; 2015 Jun; 31(6):1057-61. PubMed ID: 25851062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
    Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
    Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of rivaroxaban in sickle cell disease and venous thromboembolism: A case report.
    Rozi W; Ali EAH; Al-Mashdali AF; Abdelrazek M; Yassin MA
    Medicine (Baltimore); 2021 Dec; 100(51):e27988. PubMed ID: 34941038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study.
    Fermann GJ; Erkens PM; Prins MH; Wells PS; Pap ÁF; Lensing AW
    Acad Emerg Med; 2015 Mar; 22(3):299-307. PubMed ID: 25716463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
    Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
    Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergency Department Discharge of Pulmonary Embolus Patients.
    Frank Peacock W; Coleman CI; Diercks DB; Francis S; Kabrhel C; Keay C; Kline JA; Manteuffel J; Wildgoose P; Xiang J; Singer AJ
    Acad Emerg Med; 2018 Sep; 25(9):995-1003. PubMed ID: 29757489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban.
    Weeda ER; Wells PS; Peacock WF; Fermann GJ; Baugh CW; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
    Int J Cardiol; 2016 Nov; 222():846-849. PubMed ID: 27522388
    [No Abstract]   [Full Text] [Related]  

  • 16. Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism.
    Wang L; Baser O; Wells P; Peacock WF; Coleman CI; Fermann GJ; Schein J; Crivera C
    Clin Ther; 2017 Jul; 39(7):1426-1436.e2. PubMed ID: 28652016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
    Kabuki T; Nakanishi R; Hisatake S; Fujii T; Dobashi S; Wakakura S; Kiuchi S; Fujino T; Ikeda T
    J Cardiol; 2017 Aug; 70(2):163-168. PubMed ID: 27979674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism.
    Weeda ER; Kohn CG; Peacock WF; Fermann GJ; Crivera C; Schein JR; Coleman CI
    Pharmacotherapy; 2016 Oct; 36(10):1109-1115. PubMed ID: 27548074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial.
    Barco S; Schmidtmann I; Ageno W; Bauersachs RM; Becattini C; Bernardi E; Beyer-Westendorf J; Bonacchini L; Brachmann J; Christ M; Czihal M; Duerschmied D; Empen K; Espinola-Klein C; Ficker JH; Fonseca C; Genth-Zotz S; Jiménez D; Harjola VP; Held M; Iogna Prat L; Lange TJ; Manolis A; Meyer A; Mustonen P; Rauch-Kroehnert U; Ruiz-Artacho P; Schellong S; Schwaiblmair M; Stahrenberg R; Westerweel PE; Wild PS; Konstantinides SV; Lankeit M;
    Eur Heart J; 2020 Jan; 41(4):509-518. PubMed ID: 31120118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidisciplinary approach to the management of patients with pulmonary embolism and deep vein thrombosis: a consensus on diagnosis, traditional therapy and therapy with rivaroxaban.
    Imberti D; Becattini C; Bernardi E; Camporese G; Cuccia C; Dentali F; Paretti D
    Intern Emerg Med; 2018 Oct; 13(7):1037-1049. PubMed ID: 29520700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.